News

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

October 27, 2016
BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory BowelDisease Can J Gastroenterol Hepatol. 2016;2016:2483261. Epub 2016 Sep 28.DOI:10.1155/2016/2483261.  PMID: 27774443.  This Canadian study represents how FCAL testing is utilized in the field for monitoring disease activity in IBD.  The reference for the cut-off
Read more

Evaluation of the BÜHLMANN fCAL® turbo test at Bioanalytica Lucerne

October 13, 2016

Interview with the leader of this evaluation study, Yvonne Schallberger about her positive experiences with the BÜHLMANN fCAL® turbo assay and with the CALEX® Cap stool extraction device which has also been used successfully with the ScheBo® Pancreatic Elastase. Click here.  

Read more

Proactive Therapeutic Drug Monitoring of Infliximab: A Comparative Study of a New Point-of-Care Quantitative Test with Two Established ELISA Assays

October 5, 2016
BÜHLMANN Quantum Blue® Infliximab Trough Level Assay Citation: Afonso J, Lopes S et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. PMID: 27507790 First Publication using our Quantum Blue® Infliximab Trough Level Assay We are very
Read more

Visit us at UEGW2016

October 5, 2016
Exhibition Booth

BÜHLMANN will be present from October 15th to 19th at the 2016 United European Gastro Week Visit us at booth #31 in Hall X2 Exhibtion Highlights: Presentation of the first Infliximab Therapeutic Drug Montioring Point-of-Care Rapid Test Presentation of the first truly random access BÜHLMANN fCAL turbo assay Oral Presentation #OP247: 18 months market experience

Read more